Both in Pharmaceuticals
Impact BioMedical vs Lite Strategy
Over the past year IBO returned −45.1% and LITS returned −36.3%; their daily moves had a correlation of 0.12.
IBO −45.1% LITS −36.3%Growth of $1, one year, split-adjusted
| Metric | IBO | LITS |
|---|---|---|
| Price | $3.99 | $1.23 |
| Market cap | $34.1M | $37.4M |
| Today | +12.39% | +6.49% |
| 1 month | −28.8% | −10.5% |
| 6 months | −52.1% | +7.0% |
| Year to date | −37.4% | −6.8% |
| 1 year | −45.8% | −41.1% |
| Revenue growth (YoY) | −57.1% | — |
| Gross margin | −533.3% | — |
| Net margin | −23300.0% | — |
| P/E (TTM) | 43.2× | — |
| Price / sales | 974.0× | — |
| Net cash | $10.0K | $5.7M |
| Dividend yield | — | — |
| Volatility (60d) | 736.6% | 78.5% |
| Short % of float | 0.2% | 0.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).